Literature DB >> 31102786

Activated NF-κB/Nrf2 and Wnt/β-catenin pathways are associated with lipid metabolism in CKD patients with microalbuminuria and macroalbuminuria.

Ya-Long Feng1, Hua Chen1, Dan-Qian Chen1, Nosratola D Vaziri2, Wei Su3, Shi-Xing Ma3, You-Quan Shang3, Jia-Rong Mao4, Xiao-Yong Yu4, Li Zhang5, Yan Guo6, Ying-Yong Zhao7.   

Abstract

Early diagnosis of CKD patients at risk for microalbuminuria or macroalbuminuria could facilitate clinical outcomes and long-term survival. Considering the few and limited efficacy of current biomarkers in early detection, we aim to discover plasma lipids that effectively predict the development of CKD paitents with microalbuminuria or macroalbuminuria. A total of 380 healthy controls and 1156 patients with CKD stages 3 to 5 were stratified by urine albumin-creatinine ratio as microalbuminuria (30-300 mg/g) and macroalbuminuria (>300 mg/g). Fasting plasma samples were determined by UPLC-HDMS based on lipidomics. Quantitative real-time polymerase chain reaction, Western blot and immunohistochemical analyses were used to validate the lipid metabolism-associated pathways. Pathway analysis demonstrated that these lipids were closely associated with PPARγ, inflammatory mediator regulation of TRP channels and RAS signaling, which were intimately involved in activated NF-κB and Nrf2 pathways. We further carried out pathway validation and demonstrated that NF-κB pathway was activated in patients with macroalbuminuria compared with CKD patients with microalbuminuria, while Nrf2-associated protein expression was downregulated, which was accompanied by the up-regulation of Wnt/β-catenin signaling pathway. Four lipids including DTA, 5,8-TDA, GGD3 and DHA that showed great potential in the discrimination of CKD patients with microalbuminuria and healthy controls were selected by logistic regression analysis. Additionally, six lipid species including CDCA, glucosylceramide, GGD2, TTA, DHA and EDA that contributed to the discrimination of CKD patients with microalbuminuria and macroalbuminuria were selected by logistic LASSO regression Gangliosides were first identified and might be promising therapeutic targets for CKD patients with the different degree of albuminuria. Collectively, this study first demonstrates the association of plasma inflammation, oxidative stress, Wnt/β-catenin and lipid metabolism in CKD patients with microalbuminuria and macroalbuminuria.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chronic kidney disease; Inflammation; Lipid biomarker; Lipidomics; Macroalbuminuria; Microalbuminuria

Year:  2019        PMID: 31102786     DOI: 10.1016/j.bbadis.2019.05.010

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Basis Dis        ISSN: 0925-4439            Impact factor:   5.187


  18 in total

1.  Integrative phosphatidylcholine metabolism through phospholipase A2 in rats with chronic kidney disease.

Authors:  Yan-Ni Wang; Zhi-Hao Zhang; Hong-Jiao Liu; Zhi-Yuan Guo; Liang Zou; Ya-Mei Zhang; Ying-Yong Zhao
Journal:  Acta Pharmacol Sin       Date:  2022-08-03       Impact factor: 7.169

Review 2.  Lipidomic approaches to dissect dysregulated lipid metabolism in kidney disease.

Authors:  Judy Baek; Chenchen He; Farsad Afshinnia; George Michailidis; Subramaniam Pennathur
Journal:  Nat Rev Nephrol       Date:  2021-10-06       Impact factor: 42.439

3.  Alleviation by Mahuang Fuzi and Shenzhuo Decoction in High Glucose-Induced Podocyte Injury by Inhibiting the Activation of Wnt/β-Catenin Signaling Pathway, Resulting in Activation of Podocyte Autophagy.

Authors:  Haoran Dai; Fei Liu; Xinping Qiu; Wenbin Liu; Zhaocheng Dong; Yingmin Jia; Zhendong Feng; Zhiyuan Liu; Qihan Zhao; Yu Gao; Zihan Zhang; Chang Gao; Songge Sun; Xuefei Tian; Baoli Liu
Journal:  Evid Based Complement Alternat Med       Date:  2020-09-03       Impact factor: 2.629

4.  Poricoic acid A as a modulator of TPH-1 expression inhibits renal fibrosis via modulating protein stability of β-catenin and β-catenin-mediated transcription.

Authors:  Dan-Qian Chen; Xia-Qing Wu; Lin Chen; He-He Hu; Yan-Ni Wang; Ying-Yong Zhao
Journal:  Ther Adv Chronic Dis       Date:  2020-09-30       Impact factor: 5.091

Review 5.  Druggability of lipid metabolism modulation against renal fibrosis.

Authors:  Yuan-Yuan Chen; Xiao-Guang Chen; Sen Zhang
Journal:  Acta Pharmacol Sin       Date:  2021-05-14       Impact factor: 6.150

6.  Sirt6 deficiency aggravates angiotensin II-induced cholesterol accumulation and injury in podocytes.

Authors:  Qian Yang; Jijia Hu; Yingjie Yang; Zhaowei Chen; Jun Feng; Zijing Zhu; Huiming Wang; Dingping Yang; Wei Liang; Guohua Ding
Journal:  Theranostics       Date:  2020-06-12       Impact factor: 11.556

Review 7.  Aryl hydrocarbon receptor activation mediates kidney disease and renal cell carcinoma.

Authors:  Hui Zhao; Lin Chen; Tian Yang; Ya-Long Feng; Nosratola D Vaziri; Bao-Li Liu; Qing-Quan Liu; Yan Guo; Ying-Yong Zhao
Journal:  J Transl Med       Date:  2019-09-05       Impact factor: 5.531

Review 8.  Advances in the Progression and Prognosis Biomarkers of Chronic Kidney Disease.

Authors:  Zhonghong Yan; Guanran Wang; Xingyang Shi
Journal:  Front Pharmacol       Date:  2021-12-21       Impact factor: 5.810

9.  Metabolic rewiring of the hypertensive kidney.

Authors:  Markus M Rinschen; Oleg Palygin; Carlos Guijas; Amelia Palermo; Nicolas Palacio-Escat; Xavier Domingo-Almenara; Rafael Montenegro-Burke; Julio Saez-Rodriguez; Alexander Staruschenko; Gary Siuzdak
Journal:  Sci Signal       Date:  2019-12-10       Impact factor: 8.192

Review 10.  Chronic Inflammation in Chronic Kidney Disease Progression: Role of Nrf2.

Authors:  Peter Stenvinkel; Glenn M Chertow; Prasad Devarajan; Adeera Levin; Sharon P Andreoli; Sripal Bangalore; Bradley A Warady
Journal:  Kidney Int Rep       Date:  2021-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.